{
    "ticker": "RAPT",
    "name": "RAPT Therapeutics, Inc.",
    "description": "RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with cancer and other serious diseases. Founded in 2016 and based in San Francisco, California, RAPT is focused on harnessing the power of the immune system to treat a variety of cancers through its proprietary drug discovery platform. The company\u2019s lead product candidates are designed to selectively target and activate the immune system\u2019s ability to fight tumors. RAPT\u2019s lead candidate, RPT193, is a first-in-class oral small molecule that inhibits the CCR4 receptor, which plays a critical role in the immune system's response to cancer. RAPT is committed to advancing its therapies through rigorous clinical trials and has established several partnerships with leading research institutions. By focusing on precision medicine, RAPT aims to transform the treatment landscape for oncology and bring meaningful advancements to patients suffering from these challenging conditions. The company's mission is to improve patient outcomes by delivering innovative immunotherapies that can provide lasting benefits while minimizing side effects.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2016",
    "website": "https://www.rapt.com",
    "ceo": "Peter L. Johnson",
    "social_media": {
        "twitter": "https://twitter.com/RaptTherapeutics",
        "linkedin": "https://www.linkedin.com/company/rapt-therapeutics/"
    },
    "investor_relations": "https://investors.rapt.com",
    "key_executives": [
        {
            "name": "Peter L. Johnson",
            "position": "CEO"
        },
        {
            "name": "Richard A. Heyman",
            "position": "Chairman"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Candidates",
            "products": [
                "RPT193",
                "RPT175"
            ]
        }
    ],
    "seo": {
        "meta_title": "RAPT Therapeutics, Inc. | Immuno-Oncology and Innovative Therapies",
        "meta_description": "Explore RAPT Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for cancer treatment through immune system activation.",
        "keywords": [
            "RAPT Therapeutics",
            "Immunotherapy",
            "Cancer Treatment",
            "Biopharmaceuticals",
            "CCR4 Inhibitor"
        ]
    },
    "faq": [
        {
            "question": "What does RAPT Therapeutics focus on?",
            "answer": "RAPT Therapeutics focuses on developing innovative immunotherapies for cancer and other serious diseases."
        },
        {
            "question": "Who is the CEO of RAPT Therapeutics?",
            "answer": "Peter L. Johnson is the CEO of RAPT Therapeutics, Inc."
        },
        {
            "question": "Where is RAPT Therapeutics headquartered?",
            "answer": "RAPT Therapeutics is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are RAPT's main product candidates?",
            "answer": "RAPT's main product candidates include RPT193 and RPT175."
        },
        {
            "question": "When was RAPT Therapeutics founded?",
            "answer": "RAPT Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "MRNA",
        "BMY",
        "EXEL",
        "REGN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "JNJ",
        "PFE"
    ]
}